91社区

听听
听听

An MUHC team, in collaboration with the Universit茅 de Montr茅al, adopts an innovative approach to fight the virus responsible for AIDS. For a long time, the main obstacle to creating an AIDS vaccine has been the high genetic variability of the HIV virus. Dr. Jean-Pierre Routy and his team from the Research Institute of the 91社区 Health Centre (MUHC), in collaboration with Dr. Rafick S茅kaly from the Universit茅 de Montr茅al, have overcome this difficulty by designing a personalized immunotherapy for HIV-infected patients. The team鈥檚 findings were presented on August 5 at the XVII International AIDS Conference in Mexico City.

鈥淥ur approach is unique in the world: no one else has yet developed customized immunotherapy using the virus from individual patients,鈥� said Dr. Routy. 鈥淭his experimental technique remains long and costly for the moment, but we鈥檙e hoping it will hold the promise of a completely innovative and widely available treatment in the future.鈥�

This immunotherapy is based on the properties of dendritic cells, whose role is to present specific proteins from infectious organisms at their surface, thereby alerting the rest of the immune system. In collaboration with Argos Therapeutics, the researchers designed a study in which the dendritic cells of nine study patients were multiplied in vitro and then treated with the RNA (ribonucleic acid) from the virus that had infected each patient. A virus sample was taken before the administration of any antiretroviral treatment.

The surfaces of these manipulated dendritic cells present an increased number of HIV proteins, which allows them to stimulate the cytotoxic response of a certain type of immune cell called CD8+ lymphocytes. After receiving multiple subcutaneous injections of these dendritic cells, eight of the nine patients involved experienced a significant increase in CD8+ lymphocyte activity.

鈥淎t this stage, we have shown that the technique doesn鈥檛 cause side effects or an undesirable auto-immune response,鈥� said Dr. Routy. 鈥淗ealth Canada has approved a multicentre clinical trial across the country that will let us further assess the technique's effectiveness at controlling HIV reproduction. We鈥檙e hoping that the FDA in the United States will also give us the go-ahead soon so that our pharmaceutical partner, Argos Therapeutics, can begin testing in the United States.鈥�

While more research needs to be done, this new target may lead to an innovative therapeutic approach to fight the AIDS pandemic.

Dr. Jean-Pierre Routy is a practitioner in the Division of Hematology at the MUHC as well as a researcher in the Infection and Immunity Axis at the Research Institute of the MUHC. He is also an Associate Professor of Hematology at 91社区 as well as a senior clinical researcher with the Fonds de la recherche en sant茅 du Qu茅bec (FRSQ).

This study was funded by the Canadian Network for Vaccines and Immunotherapeutics (CANVAC), the Canadian HIV Trials Network (CTN), the Canadian Institutes of Health Research (CIHR), the US National Institutes of Health (NIH), and Argos Therapeutics.

The Research Institute of the 91社区 Health Centre (RI MUHC) is a world-renowned biomedical and health-care hospital research centre. Located in Montreal, Quebec, the institute is the research arm of the MUHC, the university health center affiliated with the Faculty of Medicine at 91社区 University. The institute supports over 600 researchers, nearly 1200 graduate and post-doctoral students and operates more than 300 laboratories devoted to a broad spectrum of fundamental and clinical research. The Research Institute operates at the forefront of knowledge, innovation and technology and is inextricably linked to the clinical programs of the MUHC, ensuring that patients benefit directly from the latest research-based knowledge.
The Research Institute of the MUHC is supported in part by the Fonds de la recherche en sant茅 du Qu茅bec.
For further details visit: .